Scientific Advisory Board
Prof. Dr. Christoph Rader
Prof. Christoph Rader is Associate Professor with Tenure position in the Department of Cancer Biology and the Department of Molecular Therapeutics at The Scripps Research Institute (TSRI) in Jupiter, Florida, USA. Before this he was principal investigator at the National Cancer Institute (NCI) in Bethesda, Maryland, USA.
Prof. Rader studied biochemistry and molecular biology at the University of Bayreuth in Germany and at the University of Zurich in Switzerland, where he also obtained his PhD with honors in 1995 for work on immunoglobulin superfamily molecules. After this he did several years of postdoctoral research in the laboratory of Carlos F. Barbas III at TSRI in La Jolla, California, USA, where he specialized in antibody engineering, phage display, and catalytic antibody technologies. Following his promotion to Assistant Professor at TSRI, he won the prestigious Investigator Award from the Cancer Research Institute in 2000.
Prof. Rader’s work contributed to the invention of chemically programmed monoclonal antibodies, a cross between traditional small molecules and a certain monoclonal antibody. This innovation was subsequently commercialized, and is the basis for several new drugs currently in ongoing phase I and II clinical trials for the treatment of various cancers and metabolic diseases. Prof. Rader joined the NCI in 2003 to build and lead the Antibody Technology Section in the Experimental Transplantation and Immunology Branch. In 2007, he received the NCI Director's Intramural Innovation Award for Principal Investigators for a novel chemical programming concept.
His achievements include more than 80 publications and 13 patents or patent applications in the area of antibody engineering and antibody drug/toxin conjugation technologies.
Prof. Dr. Thomas Winkler
Prof. Thomas Winkler is Associate Professor for Genetics at the Nikolaus-Fiebinger Centre for Molecular Medicine of the University of Erlangen-Nuremberg, Germany, where his research focuses on understanding the genetic mechanisms for the early B-cell development and how defects in this may lead to loss of self-tolerance and the development of autoimmunity. In addition, his laboratory has a strong interest in understanding antibody- and B-lineage cell mediated protection against viral infections using cytomegalovirus as a model system in mice and in translational approaches for the benefit of patients.
Prof. Winkler has studied Biology at the University of Erlangen and did his PhD work in the laboratory of Prof. Jochen Kalden, a world-renowned rheumatologist and autoimmune Immunologist. After that he did post-doctoral work on B cell Immunology at the Basel Institute for Immunology, a triple Nobel-Prize awarded Swiss academic Institute. Following his post-doctoral research he became principal investigator at the Division of Molecular Medicine, at the University of Erlangen-Nuremberg, where in 2001 he was appointed Associate Professor for Genetics.
Prof. Winkler is a renowned Molecular Immunologist in the field of of research with antibody-producing B cells, and among other competitive grants has been awarded highly competivite Collaborative Research Centre (SFB) grants of the German Research Foundation, and of the Bavarian Immunotherapy Network (BayImmuNet: www.bayimmunet.de/en/).
Prof. Thomas Winkler has published several dozens scientific papers, including seminal papers in high-impact Journals, like Science, J. Exp. Med., PNAS, Immunity and Blood.
Prof. Dr. Sai Reddy
Since 2012, Prof. Sai Reddy is a Tenure-track Assistant Professor of Biomolecular Engineering at ETH Zurich in the Deptartment of Biosystems Science & Engineering (D-BSSE, Basel, Switzerland). He is the principle investigator of the Laboratory for Systems Immunotechnology (http://www.bsse.ethz.ch/lsi/), whose research is focused on the nascent field of experimental systems immunology, which is at the intersection of Biomolecular Engineering, Systems Biology, and Immunology.
Prof. Reddy holds B.S. and M.S. degrees in Biomedical Engineering from Northwestern University (Evanston, IL, USA). In 2008 he obtained his Ph.D. at Ecolé Polytechnique Féderale de Lausanne (EPFL) in Bioengineering and Biotechnology in, where his research was centered on developing a novel nanoparticle vaccine technology, of which he was awarded KPMG tomorrow’s market award.
Prof. Reddy then moved to University of Texas, Austin (USA) for his post-doctoral research, where he worked on protein and antibody engineering. This work led to the development of a breakthrough technology allowing monoclonal antibody discovery without screening, which involves the combination of high-throughput DNA sequencing, Bioinformatics, and Synthetic Biology and importantly, demonstrated how Systems Immunology can impact Biotechnology.
Prof. Reddy’s research has been published in international peer-reviewed journals of high-impact, including Nature Biotechnology and PNAS, USA. He is also co-inventor of three patents related to nanoparticle vaccines, antibody engineering, and antibody discovery.
Prof. Dr. Alfred Zippelius
Prof. Alfred Zippelius, MD, is full Professor of Translational Oncology at the Departments of Medical Oncology and Biomedicine, Cancer Immunology at the University Hospital Basel, Switzerland. In these functions he is conducting clinical trials as well as supervising clinical research in his laboratory focusing on translational research in the area of cancer immunotherapy and the development of novel targeted cancer therapies.
Prof. Zippelius studied medicine at Ludwig-Maximilians-University (LMU) Munich, Germany, where he also performed experimental work for his MD thesis in the laboratory of world-renowned German Immunologist Prof. Dr. Gert Riethmüller. After this he performed post-doctoral research work as a German Research Agency (DFG)/Emmy-Noether fellow at the Ludwig Institute for Cancer Research (LICR) in Lausanne, Switzerland, and thereafter became principal investigator in the Tumor Immunology lab of the Medical Oncology Department at University Hospital Zurich, Switzerland. He was then appointed Swiss National Science Foundation (SNF) Professor and group leader of the Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel, where he subsequently became full Professor of Translational Oncology. He has full responsibility for clinical trial design and applications and the research in the Laboratory of Cancer Immunology.
Prof. Zippelius is author of over 50 high-impact publications and inventor of several patents in the field of cancer immunology. During his career he has received numerous fellowships and awards, including competitive DFG/Emmy-Noether fellowship and SNF Professorships. Prof. Zippelius serves on a number of international review and advisory boards, including review functions at the Journal of Experimental Medicine, Blood, or PNAS, and the SNF, DFG and the Dutch Cancer Society. Prof. Zippelius is also active in many national and international professional societies, including the European Society for Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO) and the European Society for Cancer Immunology and Immunotherapy.
- Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
- London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.
- Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference